Literature DB >> 15677539

Alterations of mononuclear inflammatory cells, CD4/CD8+ T cells, interleukin 1beta, and tumour necrosis factor alpha in the bronchoalveolar lavage fluid, peripheral blood, and skin of patients with systemic sclerosis.

M R Hussein1, H I Hassan, E R M Hofny, M Elkholy, N A Fatehy, A E A Abd Elmoniem, A M Ezz El-Din, O A Afifi, H G Rashed.   

Abstract

BACKGROUND: Systemic sclerosis (SSc) is a multisystem disease with underlying immune mechanisms. AIMS: To investigate the clinicopathological characteristics of the lesions; immunological alterations in the bronchoalveolar lavage fluid (BALF), peripheral blood, and skin; and correlations between the clinicopathological characteristics and immunological alterations in SSc. MATERIALS/
METHODS: Skin biopsies, BALF, and peripheral blood samples were obtained from 19 patients (18 women, one man) with SSc and six age and sex matched healthy controls (HCs). Mononuclear inflammatory cells (MICs), CD4/CD8 cells, tumour necrosis factor alpha (TNFalpha), and interleukin 1beta (IL1-1beta) concentrations were examined in all samples using histological methods, enzyme linked immunosorbent assay, and immunoperoxidase staining.
RESULTS: The mean (SD) age of the patients with SSc was 34.8 (2.6) years. Proteinuria, positive rheumatoid factor, and C reactive protein were seen in 15.8%, 26.3%, and 26.3% of patients, respectively. Compared with HCs, there were significantly higher: total MICs (macrophages, lymphocytes), neutrophils, and eosinophils in BALF, blood, and skin (all p<0.05); cytokine concentrations in BALF (TNFalpha, p<0.001; IL-1, p<0.01) and peripheral blood (p<0.01 and p<0.05); and CD8/CD4+ T cells in peripheral blood (p<0.05). Compared with HCs, lesional skin had significantly higher histiocyte cell counts (p<0.05), lower lymphocyte counts (p<0.05), and higher CD4/CD8 ratios (p<0.001). There were significant correlations between cytokine concentrations and CD8+ T cells and forced vital capacity (p<0.001 and p<0.01, respectively).
CONCLUSIONS: MICs, CD4/CD8+ cells, and cytokines are altered in SSc. These alterations correlated with the underlying disease process and therefore may have pathogenic, modulatory, and potential prognostic roles in SSc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15677539      PMCID: PMC1770564          DOI: 10.1136/jcp.2004.019224

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  51 in total

1.  Increased frequency of interleukin 4 producing CD4+ and CD8+ cells in peripheral blood from patients with systemic sclerosis.

Authors:  J Tsuji-Yamada; M Nakazawa; M Minami; T Sasaki
Journal:  J Rheumatol       Date:  2001-06       Impact factor: 4.666

2.  Human eosinophils regulate human lung- and skin-derived fibroblast properties in vitro: a role for transforming growth factor beta (TGF-beta).

Authors:  F Levi-Schaffer; E Garbuzenko; A Rubin; R Reich; D Pickholz; P Gillery; H Emonard; A Nagler; F A Maquart
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-17       Impact factor: 11.205

3.  Abnormal expression of intracellular cytokines and chemokine receptors in peripheral blood T lymphocytes from patients with systemic sclerosis.

Authors:  H Fujii; M Hasegawa; K Takehara; N Mukaida; S Sato
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

4.  Clinical features of systemic sclerosis.

Authors:  R N Al-Adhadh; T A Al-Sayed
Journal:  Saudi Med J       Date:  2001-04       Impact factor: 1.484

5.  [Bronchoalveolar lavage findings in the pulmonary impairment related to systemic sclerosis].

Authors:  Mălina Ioanăş; Diana Ioniţă; Luminiţa Cerviş; Nicoleta Bîscă; Aneta Serbănescu; Adriana Nicolau
Journal:  Pneumologia       Date:  2002 Jul-Sep

6.  Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.

Authors:  Voon H Ong; Lowri A Evans; Xu Shiwen; Ivan B Fisher; Vineeth Rajkumar; David J Abraham; Carol M Black; Christopher P Denton
Journal:  Arthritis Rheum       Date:  2003-07

7.  Dual roles of IL-4 in lung injury and fibrosis.

Authors:  François Huaux; Tianju Liu; Bridget McGarry; Matt Ullenbruch; Sem H Phan
Journal:  J Immunol       Date:  2003-02-15       Impact factor: 5.422

8.  Analysis of lymphocyte subpopulations in systemic sclerosis.

Authors:  Linete Parolin Ercole; Mariester Malvezzi; Antonio Carlos Boaretti; Shirley Ramos Utiyama; Acir Rachid
Journal:  J Investig Allergol Clin Immunol       Date:  2003       Impact factor: 4.333

9.  Loss of heterozygosity, microsatellite instability, and mismatch repair protein alterations in the radial growth phase of cutaneous malignant melanomas.

Authors:  Mahmoud R Hussein; Min Sun; Eduardo Roggero; Eulalia C Sudilovsky; Ralph J Tuthill; Gary S Wood; Oscar Sudilovsky
Journal:  Mol Carcinog       Date:  2002-05       Impact factor: 4.784

10.  Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population.

Authors:  Maureen D Mayes; James V Lacey; Jennifer Beebe-Dimmer; Brenda W Gillespie; Brenda Cooper; Timothy J Laing; David Schottenfeld
Journal:  Arthritis Rheum       Date:  2003-08
View more
  30 in total

Review 1.  Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?

Authors:  Giuseppina Stifano; Romy Beatriz Christmann
Journal:  Curr Rheumatol Rep       Date:  2016-01       Impact factor: 4.592

2.  Treatment with imatinib results in reduced IL-4-producing T cells, but increased CD4(+) T cells in the broncho-alveolar lavage of patients with systemic sclerosis.

Authors:  Anagha A Divekar; Dinesh Khanna; Fereidoun Abtin; Paul Maranian; Rajeev Saggar; Rajan Saggar; Daniel E Furst; Ram Raj Singh
Journal:  Clin Immunol       Date:  2011-09-05       Impact factor: 3.969

3.  Attenuated nitric oxide bioavailability in systemic sclerosis: Evidence from the novel assessment of passive leg movement.

Authors:  Heather L Clifton; Daniel R Machin; H Jonathan Groot; Tracy M Frech; Anthony J Donato; Russell S Richardson; D Walter Wray
Journal:  Exp Physiol       Date:  2018-08-18       Impact factor: 2.969

4.  Immunohistological analysis of immune cells in blistering skin lesions.

Authors:  Mahmoud R Hussein; Fayed Mahammad Nagy Ali; Abd-Elhady M M Omar
Journal:  J Clin Pathol       Date:  2007-01       Impact factor: 3.411

5.  Elevated serum levels of interleukin-1β and interleukin-33 in patients with systemic sclerosis in Chinese population.

Authors:  Y-J Zhang; Q Zhang; G-J Yang; J-H Tao; G-C Wu; X-L Huang; Y Duan; X-P Li; D-Q Ye; J Wang
Journal:  Z Rheumatol       Date:  2018-03       Impact factor: 1.372

6.  Fibrosis, vascular activation, and immune abnormalities resembling systemic sclerosis in bleomycin-treated Fli-1-haploinsufficient mice.

Authors:  Takashi Taniguchi; Yoshihide Asano; Kaname Akamata; Shinji Noda; Takehiro Takahashi; Yohei Ichimura; Tetsuo Toyama; Maria Trojanowska; Shinichi Sato
Journal:  Arthritis Rheumatol       Date:  2015-02       Impact factor: 10.995

7.  RGC32 Promotes Bleomycin-Induced Systemic Sclerosis in a Murine Disease Model by Modulating Classically Activated Macrophage Function.

Authors:  Chenming Sun; Shi-You Chen
Journal:  J Immunol       Date:  2018-03-05       Impact factor: 5.422

8.  S100A9 promotes human lung fibroblast cells activation through receptor for advanced glycation end-product-mediated extracellular-regulated kinase 1/2, mitogen-activated protein-kinase and nuclear factor-κB-dependent pathways.

Authors:  X Xu; H Chen; X Zhu; Y Ma; Q Liu; Y Xue; H Chu; W Wu; J Wang; H Zou
Journal:  Clin Exp Immunol       Date:  2013-09       Impact factor: 4.330

9.  Potential biomarkers for detecting pulmonary arterial hypertension in patients with systemic sclerosis.

Authors:  Paola Coral-Alvarado; Gerardo Quintana; Maria Fernanda Garces; Libia Alexandra Cepeda; Jorge Eduardo Caminos; Federico Rondon; Antonio Iglesias-Gamarra; Jose Felix Restrepo
Journal:  Rheumatol Int       Date:  2008-12-31       Impact factor: 2.631

10.  The role of B cells in systemic sclerosis.

Authors:  Marina D Kraaij; Jacob M van Laar
Journal:  Biologics       Date:  2008-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.